AAA-Rated. 64 Years of Raises. 26x Earnings. Is JNJ Still a Buy at $225?
Dividend safety score of 85. Five-year P/E mean of 21.7x. One of those numbers is reassuring. The other isn't.
1. Business Overview
Johnson & Johnson is not the company it was five years ago. In August 2023, J&J completed the separation of its Consumer Health segment, the business that owned Tylenol, Listerine, Band-Aid, and Neutrogena, by spinning it off into an independent public company called Kenvue.
What remains is a pure-play, two-segment healthcare giant: a prescription-drug business called Innovative Medicine and a surgical-and-interventional-device business called MedTech.
Together they generated $94.2 billion in revenue in fiscal year 2025, up from $78.7 billion in FY2021, with operating margins of 26.8% and free cash flow of $19.7 billion.
The Kenvue separation is the single most important strategic event in modern J&J history.
Consumer Health was the lowest-margin segment in the portfolio, and it carried the talc litigation overhang that had hung over the parent company for nearly a decade. By spinning it off, J&J shed approximately $15 billion of low-margin revenue and concentrated capital and management attention on the two segments where it could earn the highest returns: patent-protected prescription pharmaceuticals and surgical devices that lock in hospital customers.
The financial results are evident in the numbers: ROIC reached a five-year high of 17.0% in FY2025, and operating margins improved by roughly 200 basis points over the period despite gross margin compression from biosimilar competition and Medicare price negotiations.
Stock Simplifier classifies JNJ as a Phase 4: Capital Return company, steady mid-single-digit revenue growth, consistently positive operating cash flow, and substantial capital being returned to shareholders through dividends and buybacks.
The composite Stock Simplifier score is 3.8 out of 5, with the Moat rated “Wide” (5), Management rated “Great” (5), Risk rated “Moderate” (3), Growth rated “Below Average” (2), and Valuation rated “Expensive” (2).
That mix is exactly what a serious dividend investor wants to evaluate: a high-quality, slow-growing, mature compounder where the question is not whether the business is durable, but whether you are paying the right price for the cash it produces.
For paid readers thinking about JNJ as a portfolio holding: this is a company built for the back half of a dividend portfolio, not the high-growth front. The investment case rests on three pillars, a wide moat that protects current cash flows, a Dividend King track record of 64 consecutive annual dividend increases, and a balance sheet strong enough to absorb both talc litigation outcomes and patent cliffs without threatening the dividend.
We will test each of those pillars in this analysis.
2. How They Make Money
JNJ earns revenue from two distinct sources, neither of which involves direct consumer relationships in any meaningful way. Understanding the channel structure is essential because it explains why margins, pricing power, and recession resilience look the way they do.
Innovative Medicine ($60.4B, 64% of FY2025 revenue, 84% of pre-tax profit). This is the prescription pharmaceuticals business, organized around five therapeutic areas: oncology, immunology, neuroscience, cardiovascular and metabolism, and pulmonary hypertension.
The customer chain here is institutional, not consumer. Physicians prescribe based on clinical evidence. Hospitals and retail pharmacies distribute. Insurance companies, pharmacy benefit managers (PBMs), and government payors (Medicare, Medicaid, national health systems abroad) decide reimbursement and ultimately pay. The patient receives the drug but rarely makes the purchasing decision. J&J’s commercial success depends on three things in this chain: clinical data strong enough to convince physicians, formulary access negotiated with payors, and lifecycle management of patents to protect pricing.
The marquee Innovative Medicine franchises in FY2025 were Darzalex (daratumumab) for multiple myeloma at $14.35 billion in sales (up 23% year-over-year), Stelara (ustekinumab) for immunology indications at $6.08 billion (down 41.3% as US biosimilars launched in January 2025), Tremfya (guselkumab) for psoriasis and Crohn’s disease at $5.2 billion (up 40.5% as J&J transitions Stelara patients), Erleada for prostate cancer, and Carvykti (CAR-T cell therapy for multiple myeloma) which is scaling rapidly from a small base.
Roughly two-thirds of Innovative Medicine revenue comes from chronic-disease therapies where patients refill prescriptions for months or years, creating predictable recurring revenue streams.
MedTech ($33.8B, 36% of revenue, 12% pre-tax margin). This segment sells surgical instruments, orthopedic implants, electrophysiology catheters, heart-recovery devices, and vision care products.
The customer is the hospital system or ambulatory surgery center. Purchasing decisions are made by a chain that includes surgeons (who have brand preferences and switching costs from retraining), hospital procurement teams (who negotiate aggressively on price), and group purchasing organizations (which aggregate demand across multiple facilities).
Key MedTech franchises include DePuy Synthes in orthopedic reconstruction (hips, knees, spine), Biosense Webster in electrophysiology mapping and ablation catheters, Abiomed in heart recovery (acquired 2022 for $16.6B), and Shockwave Medical in intravascular lithotripsy (acquired 2024 for $13.1B).
MedTech revenue is partly per-procedure (catheters, lithotripsy) and partly capital-equipment-and-consumables (orthopedic implants installed once, then served by follow-up parts and revisions).
Geographic mix (FY2025): United States $53.8B (57% of revenue), Europe $21.5B (23%), Asia-Pacific and Africa $14.0B (15%), Western Hemisphere ex-US $4.9B (5%).
The US weighting has increased modestly over five years from 55% to 57%, reflecting stronger pharma pricing and procedure volumes domestically combined with FX headwinds and tighter government pricing controls internationally.
The US is where JNJ commands the most pricing power and where its 67.9% gross margin is built; international revenue is lower-margin and structurally more constrained by national health system negotiation.
The two segments together generate roughly $94 billion of revenue from selling, in aggregate, into perhaps 6,000 hospital systems, tens of thousands of independent surgical centers, and a global prescribing physician base measured in the millions.
The recurring nature of chronic-disease prescriptions and the switching costs of standardized hospital implant systems are what give the business its predictability rating from Stock Simplifier and its place in this analysis.
3. Financials: Five-Year Look at the Three Statements
Note: Revenue figures shown on continuing-operations basis (excluding Consumer Health/Kenvue, which was separated in August 2023). Net income volatility in FY2022–FY2024 reflects talc-related litigation reserves and special items; FY2025 net income benefited from non-recurring items including spin-off accounting and tax adjustments. Source: JNJ Form 10-K FY2024 (filed Feb 2025) and Q4/Full-Year 2025 earnings release.
The top line grew at a 4.6% compound annual rate over four years. That number understates underlying momentum because the four-year window straddles the Kenvue separation, which removed roughly $15 billion of consumer health revenue.
On a clean continuing-operations basis, the remaining pharma-and-MedTech business has grown faster, Innovative Medicine compounded at 7.3% over four years and MedTech at 10.1% (boosted by the Abiomed and Shockwave acquisitions).
Gross margin compressed by 240 basis points across the period, primarily from Stelara biosimilar pressure and IRA-driven Medicare price negotiation.
The operating margin expansion to 26.8% in FY2025 came from cost discipline and operating leverage, not pricing — Stock Simplifier’s “sales change due to price” KPI registered -3.1% in FY2025, the most negative in the five-year dataset.
R&D spending of $14.7 billion in FY2025 (15.6% of revenue) is among the largest in pharma. The FY2024 spike to $17.2 billion reflected acquired in-process R&D from the Shockwave deal; the FY2025 figure of $14.7 billion is closer to underlying organic R&D run-rate.
Balance Sheet (FY2024 vs. FY2025 Snapshot)
Source: JNJ 10-K FY2024, JNJ Q4 2025 earnings release.
The balance sheet story over the past two years is the deliberate use of leverage to fund MedTech consolidation.
Total debt rose from $36.6B at FY2024 year-end to $47.9B at FY2025 year-end as J&J financed the Shockwave Medical acquisition and other capital deployment. Even after that increase, net debt-to-EBITDA of 0.76x is investment-grade conservative, well below the 1.0x threshold that scores 100 in our dividend safety model.
Interest coverage remains north of 15x. J&J holds an AAA rating from S&P (one of only two US non-financial corporates with that rating).
The balance sheet, in short, has plenty of capacity to absorb both the remaining talc litigation and additional bolt-on M&A without endangering the dividend.
Cash Flow Statement (FY2021–FY2025)
Source: JNJ 10-K filings (FY2021–FY2024) and Q4/Full-Year 2025 earnings release. FCF = OCF – capex. Free cash flow margin in FY2025: 20.9%.
This is the most important table in the article for dividend investors. Three observations stand out.
First, free cash flow has averaged $18.4 billion annually over five years with low volatility — the coefficient of variation is approximately 0.054, well inside the “very stable” zone of our dividend safety model.
Second, dividends paid have grown every year, from $11.0B in FY2021 to $12.4B in FY2025, consuming roughly 63% of FY2025 free cash flow.
Third, total capital returned (dividends plus buybacks) of $18.4B in FY2025 represents 74.7% of operating cash flow and 93% of free cash flow — a textbook Phase 4 capital return profile. The remaining cash funds bolt-on M&A, with larger deals (like Shockwave at $13.1B) financed primarily with debt.
The combination of high gross margins, stable FCF, conservative leverage, and a 64-year dividend growth streak is the financial foundation of the entire investment thesis. We will return to these numbers in the dividend strength section.
In August 2023, Johnson & Johnson did something no $400B+ company had done in a generation: it spun off its single most recognizable business. Tylenol. Listerine. Band-Aid. Neutrogena. Gone, packaged into a new company called Kenvue and sent on its way.
What’s left is leaner, higher-margin, and harder to evaluate. Two segments instead of three. Patent-protected drugs and surgical devices. No more consumer brands, no more talc on the balance sheet (legally, though, as you’ll see, that protection has been less complete than designed).
For dividend investors, the question is simple: is the new JNJ still the dividend fortress the old JNJ was? 64 years of consecutive raises says yes. A 26x P/E against a 5-year average of 21.7x and a free cash flow payout that just crossed 60% say not so fast.
In this 6,000-word paid analysis, I work through every section a serious DIY investor needs: business, financials, moat, management, risks, growth, dividend score, and valuation. By the end, you’ll know exactly what to do with JNJ at $225.
🔒 Read the full breakdown below ↓
